TI 1007

Drug Profile

TI 1007

Alternative Names: CAR-T/CD19 - Timmune Biotech; TI-1007; TriCAR-T-CD19 adoptive immunotherapy - Timmune Biotech

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Timmune Biotech
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Jan 2018 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (ChiCTR1800014528)
  • 13 Sep 2017 Timmune Biotech plans a phase I trial for Cancer in 2017 (Timmune Biotech pipeline, September 2017)
  • 13 Sep 2017 Preclinical trials in Cancer in China (Parenteral) before September 2017 (Timmune Biotech pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top